- Home
- ETWO vs ETNB Comparison
ETWO vs ETNB Comparison
Compare ETWO & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETWO
- ETNB
- Stock Information
- Founded
- ETWO 2000
- ETNB 2018
- Country
- ETWO United States
- ETNB United States
- Employees
- ETWO N/A
- ETNB N/A
- Industry
- ETWO EDP Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- ETWO Technology
- ETNB Health Care
- Exchange
- ETWO Nasdaq
- ETNB Nasdaq
- Market Cap
- ETWO 663.4M
- ETNB 1.5B
- IPO Year
- ETWO N/A
- ETNB 2019
- Fundamental
- Price
- ETWO $3.23
- ETNB $9.75
- Analyst Decision
- ETWO Sell
- ETNB Strong Buy
- Analyst Count
- ETWO 4
- ETNB 8
- Target Price
- ETWO $2.78
- ETNB $26.43
- AVG Volume (30 Days)
- ETWO 3.5M
- ETNB 2.2M
- Earning Date
- ETWO 07-10-2025
- ETNB 08-04-2025
- Dividend Yield
- ETWO N/A
- ETNB N/A
- EPS Growth
- ETWO N/A
- ETNB N/A
- EPS
- ETWO N/A
- ETNB N/A
- Revenue
- ETWO $607,688,000.00
- ETNB N/A
- Revenue This Year
- ETWO $1.84
- ETNB N/A
- Revenue Next Year
- ETWO $2.32
- ETNB N/A
- P/E Ratio
- ETWO N/A
- ETNB N/A
- Revenue Growth
- ETWO N/A
- ETNB N/A
- 52 Week Low
- ETWO $1.75
- ETNB $4.16
- 52 Week High
- ETWO $4.82
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- ETWO 68.29
- ETNB 52.08
- Support Level
- ETWO $3.21
- ETNB $9.59
- Resistance Level
- ETWO $3.24
- ETNB $10.20
- Average True Range (ATR)
- ETWO 0.01
- ETNB 0.51
- MACD
- ETWO -0.03
- ETNB -0.12
- Stochastic Oscillator
- ETWO 66.67
- ETNB 38.79
About ETWO E2open Parent Holdings Inc.Class A
E2open Parent Holdings Inc is an end-to-end and cloud-based supply chain management SaaS platform. The company's software combines networks, data, and applications to provide a deeply embedded, mission-critical platform that allows customers to optimize the supply chain across channel shaping, business planning, logistics, trade, manufacturing, and supply management. The Group has one reportable segment consisting of cloud-based, end-to-end SCM software. Geographically, the company operates in the Americas, Europe, and Asia Pacific, out of which the majority is from the Americas.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).